You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemazepam
Accession NumberDB00231  (APRD00676)
TypeSmall Molecule
GroupsApproved
DescriptionA benzodiazepine that acts as a gamma-aminobutyric acid modulator and anti-anxiety agent. [PubChem]
Structure
Thumb
Synonyms
Restoril
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Co Temazepam Capsules 15mgCapsule15 mgOralCobalt Pharmaceuticals Company2002-08-142015-08-07Canada
Co Temazepam Capsules 30mgCapsule30 mgOralCobalt Pharmaceuticals Company2002-08-142015-08-07Canada
Dom-temazepamCapsule15 mgOralDominion Pharmacal1996-12-162016-10-25Canada
Dom-temazepamCapsule30 mgOralDominion Pharmacal1997-03-162016-10-25Canada
Gen-temazepam 15mgCapsule15 mgOralGenpharm Ulc1997-07-082009-10-15Canada
Gen-temazepam 30mgCapsule30 mgOralGenpharm Ulc1997-07-082009-10-15Canada
Ntp-temazepamCapsule15 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-temazepamCapsule30 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Nu-temazepamCapsule15 mgOralNu Pharm Inc1996-08-162012-09-04Canada
Nu-temazepamCapsule30 mgOralNu Pharm Inc1996-08-162012-09-04Canada
Penta-temazepam CapsulesCapsule15 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-temazepam CapsulesCapsule30 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PHL-temazepamCapsule30 mgOralPharmel Inc2007-07-272016-10-25Canada
PHL-temazepamCapsule15 mgOralPharmel Inc2007-07-272016-10-25Canada
PMS-temazepamCapsule15 mgOralPharmascience Inc2005-11-29Not applicableCanada
PMS-temazepamCapsule30 mgOralPharmascience Inc2005-11-29Not applicableCanada
PMS-temazepam - 15mgCapsule15 mgOralPharmascience Inc1996-10-172009-10-21Canada
PMS-temazepam - 30mgCapsule30 mgOralPharmascience Inc1996-10-172009-10-21Canada
Ratio-temazepamCapsule15 mgOralRatiopharm Inc Division Of Teva Canada Limited2001-02-192014-09-19Canada
Ratio-temazepamCapsule30 mgOralRatiopharm Inc Division Of Teva Canada Limited2001-02-192014-09-19Canada
RestorilCapsule7.5 mg/1OralMallinckrodt, Inc.2011-07-07Not applicableUs
RestorilCapsule15 mgOralAspri Pharma Canada Inc1980-12-31Not applicableCanada
RestorilCapsule7.5 mg/1OralCardinal Health2008-11-20Not applicableUs
RestorilCapsule15 mg/1OralMallinckrodt, Inc.2011-07-07Not applicableUs
RestorilCapsule30 mgOralAspri Pharma Canada Inc1980-12-31Not applicableCanada
RestorilCapsule30 mg/1OralMallinckrodt, Inc.2011-07-07Not applicableUs
RestorilCapsule22.5 mg/1OralMallinckrodt, Inc.2011-07-07Not applicableUs
TemazepamCapsule7.5 mg/1OralKAISER FOUNDATION HOSPITALS2010-03-23Not applicableUs
TemazepamCapsule7.5 mg/1OralMallinckrodt, Inc.2010-02-23Not applicableUs
TemazepamCapsule7.5 mg/1OralAmerican Health Packaging2012-02-01Not applicableUs
TemazepamCapsule22.5 mg/1OralMallinckrodt, Inc.2010-02-23Not applicableUs
Temazepam-15Capsule15 mgOralPro Doc Limitee1997-08-06Not applicableCanada
Temazepam-30Capsule30 mgOralPro Doc Limitee1997-08-06Not applicableCanada
Teva-temazepamCapsule30 mgOralTeva Canada Limited1996-12-18Not applicableCanada
Teva-temazepamCapsule15 mgOralTeva Canada Limited1996-12-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-temazepamCapsule15 mgOralApotex Inc1996-10-02Not applicableCanada
Apo-temazepamCapsule30 mgOralApotex Inc1996-10-02Not applicableCanada
TemazepamCapsule30 mg/1OralCardinal Health2011-02-04Not applicableUs
TemazepamCapsule7.5 mg/1OralQualitest Pharmaceuticals2015-07-31Not applicableUs
TemazepamCapsule7.5 mg/1OralMc Kesson Packaging Services1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralMc Kesson Contract Packaging2011-12-06Not applicableUs
TemazepamCapsule7.5 mg/1OralLiberty Pharmaceuticals, Inc.2012-06-28Not applicableUs
TemazepamCapsule15 mg/1OralMylan Institutional Inc.1997-04-29Not applicableUs
TemazepamCapsule7.5 mg/1OralNovel Laboratories, Inc.2012-06-22Not applicableUs
TemazepamCapsule30 mg/1OralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs
TemazepamCapsule15 mg/1OralKAISER FOUNDATION HOSPITALS2003-06-02Not applicableUs
TemazepamCapsule15 mg/1OralDIRECT RX2015-01-01Not applicableUs
TemazepamCapsule30 mg/1OralAphena Pharma Solutions Tennessee, Llc1987-08-03Not applicableUs
TemazepamCapsule15 mg/1OralTYA Pharmaceuticals1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-08-03Not applicableUs
TemazepamCapsule15 mg/1OralSTAT Rx USA LLC1987-08-07Not applicableUs
TemazepamCapsule15 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-12Not applicableUs
TemazepamCapsule15 mg/1OralAphena Pharma Solutions Tennessee, Llc1988-01-12Not applicableUs
TemazepamCapsule7.5 mg/1OralMajor Pharmaceuticals2015-03-25Not applicableUs
TemazepamCapsule30 mg/1OralA S Medication Solutions1995-01-23Not applicableUs
TemazepamCapsule15 mg/1OralH.J. Harkins Company, Inc.1987-04-21Not applicableUs
TemazepamCapsule7.5 mg/1OralAv Kare, Inc.2015-08-25Not applicableUs
TemazepamCapsule15 mg/1OralPd Rx Pharmaceuticals, Inc.1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralPhysicians Total Care, Inc.2005-01-11Not applicableUs
TemazepamCapsule22.5 mg/1OralMylan Pharmaceuticals Inc.2009-06-15Not applicableUs
TemazepamCapsule30 mg/1OralProficient Rx LP1987-04-21Not applicableUs
TemazepamCapsule7.5 mg/1OralAscend Laboratories, LLC2012-06-28Not applicableUs
TemazepamCapsule22.5 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-05-23Not applicableUs
TemazepamCapsule15 mg/1OralUnit Dose Services1987-08-03Not applicableUs
TemazepamCapsule30 mg/1OralLake Erie Medical DBA Quality Care Products LLC1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralCardinal Health2011-02-04Not applicableUs
TemazepamCapsule15 mg/1OralQualitest Pharmaceuticals2015-07-31Not applicableUs
TemazepamCapsule30 mg/1OralMc Kesson Packaging Services1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralMc Kesson Contract Packaging2011-11-21Not applicableUs
TemazepamCapsule15 mg/1OralLiberty Pharmaceuticals, Inc.1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralMylan Institutional Inc.1997-05-02Not applicableUs
TemazepamCapsule15 mg/1OralNovel Laboratories, Inc.2009-10-01Not applicableUs
TemazepamCapsule15 mg/1OralRebel Distributors Corp1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralA S Medication Solutions Llc1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralActavis Elizabeth LLC1995-01-23Not applicableUs
TemazepamCapsule30 mg/1OralDIRECT RX2015-01-01Not applicableUs
TemazepamCapsule30 mg/1OralAphena Pharma Solutions Tennessee, Llc1988-01-12Not applicableUs
TemazepamCapsule15 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-05-23Not applicableUs
TemazepamCapsule30 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
TemazepamCapsule30 mg/1OralPd Rx Pharmaceuticals, Inc.1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-12Not applicableUs
TemazepamCapsule30 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs
TemazepamCapsule15 mg/1OralREMEDYREPACK INC.2014-03-19Not applicableUs
TemazepamCapsule15 mg/1OralA S Medication Solutions1995-01-23Not applicableUs
TemazepamCapsule7.5 mg/1OralMutual Pharmaceutical Company, Inc.2009-09-09Not applicableUs
TemazepamCapsule30 mg/1OralSTAT Rx USA LLC2010-05-24Not applicableUs
TemazepamCapsule15 mg/1OralCardinal Health1988-01-122016-02-25Us
TemazepamCapsule15 mg/1OralMylan Pharmaceuticals Inc.1986-07-10Not applicableUs
TemazepamCapsule15 mg/1Oralbryant ranch prepack1987-04-21Not applicableUs
TemazepamCapsule22.5 mg/1OralAscend Laboratories, LLC2012-06-28Not applicableUs
TemazepamCapsule30 mg/1OralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
TemazepamCapsule30 mg/1OralUnit Dose Services1987-08-03Not applicableUs
TemazepamCapsule15 mg/1OralLake Erie Medical DBA Quality Care Products LLC1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralREMEDYREPACK INC.2013-03-26Not applicableUs
TemazepamCapsule22.5 mg/1OralNovel Laboratories, Inc.2012-06-22Not applicableUs
TemazepamCapsule15 mg/1OralCardinal Health2012-10-25Not applicableUs
TemazepamCapsule22.5 mg/1OralQualitest Pharmaceuticals2015-07-31Not applicableUs
TemazepamCapsule15 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-09-13Not applicableUs
TemazepamCapsule30 mg/1OralLiberty Pharmaceuticals, Inc.1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralA S Medication Solutions Llc1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralRebel Distributors Corp1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralA S Medication Solutions Llc1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralActavis Elizabeth LLC1995-01-23Not applicableUs
TemazepamCapsule15 mg/1OralProficient Rx LP1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralAscend Laboratories, LLC1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-05-23Not applicableUs
TemazepamCapsule15 mg/1OralGolden State Medical Supply, Inc.2014-01-10Not applicableUs
TemazepamCapsule15 mg/1OralSandoz Inc1988-01-12Not applicableUs
TemazepamCapsule15 mg/1OralAphena Pharma Solutions Tennessee, Llc1987-08-03Not applicableUs
TemazepamCapsule7.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-03-25Not applicableUs
TemazepamCapsule30 mg/1OralDIRECT RX2014-01-01Not applicableUs
TemazepamCapsule15 mg/1OralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs
TemazepamCapsule15 mg/1OralSTAT Rx USA LLC2010-05-24Not applicableUs
TemazepamCapsule30 mg/1OralCardinal Health1988-01-122016-02-25Us
TemazepamCapsule30 mg/1OralMylan Pharmaceuticals Inc.1986-07-10Not applicableUs
TemazepamCapsule30 mg/1Oralbryant ranch prepack1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
TemazepamCapsule15 mg/1OralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
TemazepamCapsule22.5 mg/1OralUnit Dose Services2012-06-28Not applicableUs
TemazepamCapsule22.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-06-28Not applicableUs
TemazepamCapsule22.5 mg/1OralLiberty Pharmaceuticals, Inc.2012-06-28Not applicableUs
TemazepamCapsule30 mg/1OralH.J. Harkins Company, Inc.1987-04-21Not applicableUs
TemazepamCapsule30 mg/1OralNovel Laboratories, Inc.2009-10-01Not applicableUs
TemazepamCapsule30 mg/1OralCardinal Health2012-10-25Not applicableUs
TemazepamCapsule30 mg/1OralQualitest Pharmaceuticals2015-07-31Not applicableUs
TemazepamCapsule30 mg/1OralTYA Pharmaceuticals1988-01-12Not applicableUs
TemazepamCapsule30 mg/1OralAscend Laboratories, LLC1987-04-21Not applicableUs
TemazepamCapsule7.5 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-05-23Not applicableUs
TemazepamCapsule30 mg/1OralA S Medication Solutions Llc1987-04-21Not applicableUs
TemazepamCapsule15 mg/1OralRx Change Co.2014-11-15Not applicableUs
TemazepamCapsule15 mg/1OralPhysicians Total Care, Inc.2008-01-10Not applicableUs
TemazepamCapsule7.5 mg/1OralMylan Pharmaceuticals Inc.2010-05-18Not applicableUs
TemazepamCapsule30 mg/1OralProficient Rx LP1986-07-10Not applicableUs
TemazepamCapsule30 mg/1OralGolden State Medical Supply, Inc.2014-01-10Not applicableUs
TemazepamCapsule30 mg/1OralSandoz Inc1988-01-12Not applicableUs
TemazepamCapsule15 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs
TemazepamCapsule7.5 mg/1OralProficient Rx LP2009-09-09Not applicableUs
TemazepamCapsule15 mg/1OralDIRECT RX2014-01-01Not applicableUs
TemazepamCapsule22.5 mg/1OralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs
TemazepamCapsule7.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EuhypnosNot Available
NorkotralNot Available
NormisonNot Available
NortemNot Available
RemestanNot Available
TemazeNot Available
TemtabsNot Available
Brand mixtures
NameLabellerIngredients
StrazepamPhysician Therapeutics Llc
SaltsNot Available
Categories
UNIICHB1QD2QSS
CAS number846-50-4
WeightAverage: 300.74
Monoisotopic: 300.066555377
Chemical FormulaC16H13ClN2O2
InChI KeySEQDDYPDSLOBDC-UHFFFAOYSA-N
InChI
InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
IUPAC Name
7-chloro-3-hydroxy-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1
Pharmacology
IndicationFor the short-term treatment of insomnia (generally 7-10 days).
Structured Indications
PharmacodynamicsTemazepam is a benzodiazepine used as a hypnotic agent in the management of insomnia. Temazepam produces CNS depression at limbic, thalamic, and hypothalamic levels of the CNS. Temazepam increases the affinity of the neurotransmitter gamma-aminobutyric acid (GABA) for GABA receptors by binding to benzodiazepine receptors. Results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Gamma-aminobutyric acid receptor subunit beta-1Proteinyes
potentiator
HumanP18505 details
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Gamma-aminobutyric acid receptor subunit gamma-1Proteinyes
potentiator
HumanQ8N1C3 details
Gamma-aminobutyric acid receptor subunit gamma-2Proteinyes
potentiator
HumanP18507 details
Gamma-aminobutyric acid receptor subunit gamma-3Proteinyes
potentiator
HumanQ99928 details
Gamma-aminobutyric acid receptor subunit deltaProteinyes
potentiator
HumanO14764 details
Gamma-aminobutyric acid receptor subunit epsilonProteinyes
potentiator
HumanP78334 details
Gamma-aminobutyric acid receptor subunit piProteinyes
potentiator
HumanO00591 details
Gamma-aminobutyric acid receptor subunit rho-1Proteinyes
potentiator
HumanP24046 details
Gamma-aminobutyric acid receptor subunit rho-2Proteinyes
potentiator
HumanP28476 details
Gamma-aminobutyric acid receptor subunit rho-3Proteinyes
potentiator
HumanA8MPY1 details
Gamma-aminobutyric acid receptor subunit thetaProteinyes
potentiator
HumanQ9UN88 details
Translocator proteinProteinunknown
other
HumanP30536 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionWell absorbed, minimal first-pass metabolism.
Volume of distributionNot Available
Protein binding96%
Metabolism

Hepatic. Temazepam is completely metabolized through conjugation prior to excretion. The major metabolite is the O-conjugate of temazepam (90%).

SubstrateEnzymesProduct
Temazepam
OxazepamDetails
Temazepam
Not Available
Oxazepam glucuronideDetails
Route of eliminationTemazepam was completely metabolized through conjugation prior to excretion; 80% to 90% of the dose appeared in the urine.
Half life10-20 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Temazepam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Temazepam can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Temazepam is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Temazepam is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Temazepam is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Alprazolam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Temazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Temazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Temazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Temazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Temazepam is combined with Amperozide.Experimental
AprepitantThe serum concentration of Temazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Temazepam can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Asenapine.Approved
AtazanavirThe metabolism of Temazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Temazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Azaperone.Vet Approved
AzelastineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Temazepam is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Temazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Temazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Temazepam is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Temazepam can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Temazepam can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Temazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Temazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Bupivacaine.Approved, Investigational
BuprenorphineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Temazepam is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Temazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Temazepam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Butorphanol.Approved, Illicit, Vet Approved
CapecitabineThe metabolism of Temazepam can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Temazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Temazepam is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Temazepam can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Temazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Temazepam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Temazepam can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Temazepam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Temazepam can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Temazepam can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Temazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Temazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Temazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonidine.Approved
ClopidogrelThe metabolism of Temazepam can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Temazepam is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Temazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clozapine.Approved
CobicistatThe metabolism of Temazepam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Temazepam is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Temazepam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Temazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Temazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Temazepam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Temazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Temazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Temazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Temazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Temazepam can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Temazepam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Temazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Temazepam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Temazepam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Temazepam is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Temazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Temazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Temazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Temazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Temazepam is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Temazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Temazepam is combined with Doxepin.Approved
DoxorubicinThe metabolism of Temazepam can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Temazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Temazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Illicit
DronedaroneThe metabolism of Temazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Temazepam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Temazepam can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Temazepam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Temazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Temazepam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Temazepam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Temazepam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Temazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Temazepam can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Eszopiclone.Approved
EthanolTemazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Temazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Temazepam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Temazepam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Temazepam can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Temazepam is combined with Felbamate.Approved
FelodipineThe metabolism of Temazepam can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Temazepam is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Temazepam is combined with Flibanserin.Approved
FloxuridineThe metabolism of Temazepam can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Temazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Temazepam can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Temazepam can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Temazepam is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Temazepam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Temazepam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Temazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Temazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Temazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Temazepam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Temazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Temazepam is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Temazepam is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Temazepam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Temazepam can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Temazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Temazepam is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Temazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Temazepam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Temazepam is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Temazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneTemazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
IdelalisibThe serum concentration of Temazepam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Temazepam can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Temazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Temazepam can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Temazepam can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Temazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Temazepam can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Temazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Temazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Temazepam can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Temazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Temazepam is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Temazepam can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Temazepam can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Temazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Temazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Temazepam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Lofentanil.Illicit
LopinavirThe metabolism of Temazepam can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Temazepam.Approved
LosartanThe metabolism of Temazepam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Temazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Temazepam is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Temazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Temazepam can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Temazepam is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Temazepam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Temazepam is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Metaxalone.Approved
MethadoneTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Temazepam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Temazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Temazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Methohexital.Approved
MethotrimeprazineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Methylphenobarbital.Approved
MetyrosineTemazepam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Temazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Temazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Investigational
MirtazapineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Temazepam can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Temazepam can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Temazepam can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Investigational
NafcillinThe serum concentration of Temazepam can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Temazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Temazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Temazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Temazepam can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Temazepam can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Temazepam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Temazepam is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Temazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Temazepam.Approved, Investigational
OlaparibThe metabolism of Temazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Temazepam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Temazepam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Temazepam is combined with Opium.Approved, Illicit
OrphenadrineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Temazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Temazepam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Temazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone.Approved
PantoprazoleThe metabolism of Temazepam can be decreased when combined with Pantoprazole.Approved
ParaldehydeTemazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Temazepam can be decreased when combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Temazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Temazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Temazepam can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Temazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Temazepam is combined with Pimozide.Approved
PioglitazoneThe metabolism of Temazepam can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Temazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Temazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Temazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Temazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleTemazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Temazepam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Temazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Temazepam is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Temazepam is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Temazepam is combined with PSD502.Investigational
PyrimethamineThe metabolism of Temazepam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Temazepam can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Quetiapine.Approved
QuinineThe metabolism of Temazepam can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Temazepam can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Temazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Temazepam is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Temazepam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Temazepam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Temazepam.Approved
RifabutinThe metabolism of Temazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Temazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Temazepam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Temazepam is combined with Ritanserin.Investigational
RitonavirThe metabolism of Temazepam can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Romifidine.Vet Approved
RopiniroleTemazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ropivacaine.Approved
RosiglitazoneThe metabolism of Temazepam can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineTemazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Temazepam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Temazepam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Temazepam is combined with Sage 547.Investigational
SaquinavirThe metabolism of Temazepam can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Temazepam can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Temazepam can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Temazepam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Temazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Temazepam can be increased when it is combined with Simeprevir.Approved
Sodium oxybateTemazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SorafenibThe metabolism of Temazepam can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Temazepam can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Temazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Temazepam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Temazepam can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Temazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Temazepam is combined with Sulpiride.Approved
SuvorexantTemazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Temazepam can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Temazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Temazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Temazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Temazepam can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Temazepam can be decreased when combined with Telithromycin.Approved
TeriflunomideThe metabolism of Temazepam can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrodotoxin.Investigational
ThalidomideTemazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Thioridazine.Approved
ThiotepaThe metabolism of Temazepam can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiapride.Investigational
TicagrelorThe metabolism of Temazepam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Temazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Temazepam can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Temazepam can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Temazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Temazepam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Temazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe metabolism of Temazepam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Temazepam is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Temazepam is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Temazepam can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Temazepam can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Temazepam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Temazepam is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Temazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZafirlukastThe metabolism of Temazepam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Temazepam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Temazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Temazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zolazepam.Vet Approved
ZolpidemTemazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Temazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Temazepam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Temazepam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid avocado.
  • Avoid excessive quantities of coffee or tea (Caffeine).
References
Synthesis ReferenceNot Available
General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  3. Vozeh S: [Pharmacokinetic of benzodiazepines in old age]. Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. [PubMed:6118950 ]
  4. Shats V, Kozacov S: [Falls in the geriatric department: responsibility of the care-giver and the hospital]. Harefuah. 1995 Jun 1;128(11):690-3, 743. [PubMed:7557666 ]
  5. Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. [PubMed:18375 ]
External Links
ATC CodesN05CD07
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9913
Blood Brain Barrier+0.9745
Caco-2 permeable+0.7979
P-glycoprotein substrateNon-substrate0.55
P-glycoprotein inhibitor INon-inhibitor0.7388
P-glycoprotein inhibitor IIInhibitor0.546
Renal organic cation transporterNon-inhibitor0.7776
CYP450 2C9 substrateNon-substrate0.6281
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6962
CYP450 1A2 substrateInhibitor0.5916
CYP450 2C9 inhibitorNon-inhibitor0.5454
CYP450 2D6 inhibitorNon-inhibitor0.891
CYP450 2C19 inhibitorNon-inhibitor0.5615
CYP450 3A4 inhibitorNon-inhibitor0.6014
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6494
Ames testNon AMES toxic0.7974
CarcinogenicityNon-carcinogens0.8093
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0888 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9987
hERG inhibition (predictor II)Non-inhibitor0.8308
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Tyco healthcare group lp
  • Quantum pharmics ltd
  • Actavis elizabeth llc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Novel laboratories inc
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral15 mg
CapsuleOral30 mg
Kit
CapsuleOral15 mg/1
CapsuleOral22.5 mg/1
CapsuleOral30 mg/1
CapsuleOral7.5 mg/1
Prices
Unit descriptionCostUnit
Restoril 22.5 mg capsule11.37USD capsule
Restoril 7.5 mg capsule11.37USD capsule
Temazepam 22.5 mg capsule9.94USD capsule
Temazepam 7.5 mg capsule9.94USD capsule
Restoril 15 mg capsule7.87USD capsule
Restoril 30 mg capsule7.67USD capsule
Temazepam 30 mg capsule0.69USD capsule
Temazepam 15 mg capsule0.58USD capsule
Apo-Temazepam 30 mg Capsule0.14USD capsule
Co Temazepam 30 mg Capsule0.14USD capsule
Novo-Temazepam 30 mg Capsule0.14USD capsule
Pms-Temazepam 30 mg Capsule0.14USD capsule
Ratio-Temazepam 30 mg Capsule0.14USD capsule
Apo-Temazepam 15 mg Capsule0.12USD capsule
Co Temazepam 15 mg Capsule0.12USD capsule
Novo-Temazepam 15 mg Capsule0.12USD capsule
Pms-Temazepam 15 mg Capsule0.12USD capsule
Ratio-Temazepam 15 mg Capsule0.12USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5211954 No1993-05-182010-05-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point119-121 °CPhysProp
water solubility164 mg/LNot Available
logP2.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0534 mg/mLALOGPS
logP2.16ALOGPS
logP2.79ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)10.68ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity81.01 m3·mol-1ChemAxon
Polarizability30.32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-4391000000-eba55d0cdbd09c877424View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Dobbin M, Martyres RF, Clode D, Champion De Crespigny FE: Association of benzodiazepine injection with the prescription of temazepam capsules. Drug Alcohol Rev. 2003 Jun;22(2):153-7. [PubMed:12850901 ]
  2. Miller EI, Wylie FM, Oliver JS: Detection of benzodiazepines in hair using ELISA and LC-ESI-MS-MS. J Anal Toxicol. 2006 Sep;30(7):441-8. [PubMed:16959136 ]
  3. Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D: Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health. 1993 Dec;17(4):345-9. [PubMed:7911332 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. The P450 Program [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Shou M, Mei Q, Ettore MW Jr, Dai R, Baillie TA, Rushmore TH: Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53. [PubMed:10359672 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23